DIETARY EVALUATION IN TYPE-II DIABETIC SUBJECTS RANDOMLY ALLOCATED TO INSULIN, SULFONYLUREA OR DIET THERAPY

DIETARY EVALUATION IN TYPE-II DIABETIC SUBJECTS RANDOMLY ALLOCATED TO INSULIN, SULFONYLUREA OR DIET THERAPY

Bibliographic Details
Main Authors:	Eeley, E, Stratton, I, James, R, Holman, R
Format:	Journal article
Published:	1992

Similar Items

UKPDS 18: Estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy
by: Eeley, E, et al.
Published: (1996)

UKPDS 18: estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy. UK Prospective Diabetes Study Group.
by: Eeley, E, et al.
Published: (1996)

UKPDS - 6-YEAR TRIAL OF SULFONYLUREA, INSULIN AND METFORMIN THERAPY IN TYPE-2 DIABETIC-PATIENTS WITH DIET FAILURE
by: Cull, C, et al.
Published: (1995)

COMPARISON OF TREATMENT OF MILD DIABETES WITH A BASAL INSULIN SUPPLEMENT OR SULFONYLUREA
by: Holman, R, et al.
Published: (1977)

RANDOMIZED CONTROLLED TRIAL OF SULFONYLUREA THERAPY IN 227 SUBJECTS WITH PERSISTENT FASTING HYPERGLYCEMIA
by: Karunakaran, S, et al.
Published: (1995)

Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73.
by: Wright, A, et al.
Published: (2006)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus - Progressive requirement for multiple therapies (UKPDS 49)
by: Turner, R, et al.
Published: (1999)

The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose.
by: Karunakaran, S, et al.
Published: (1997)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
by: Turner, R, et al.
Published: (1999)

Risk factors for stroke in non-insulin dependent diabetic subjects.
by: Millns, H, et al.
Published: (1997)

Withdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of glycemic control: a randomized controlled trial
by: Srivanichakorn W, et al.
Published: (2015-03-01)

Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective.
by: Holman, R
Published: (2006)

Insulin therapy in type II diabetes.
by: Holman, R, et al.
Published: (1995)

United kingdom prospective diabetes study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy
by: Wright, A, et al.
Published: (1998)

UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes
by: Wright, A, et al.
Published: (1998)

Risk factors for coronary heart disease in non-insulin dependent diabetic subjects
by: Turner, R, et al.
Published: (1996)

Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).
by: Wright, A, et al.
Published: (2002)

UKPDS: Plasma leptin, obesity and plasma insulin in type 2 diabetic subjects
by: Widjaja, A, et al.
Published: (1996)

Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM.
by: Rachman, J, et al.
Published: (1998)

Clinical Characteristics of Subjects with Sulfonylurea-Dependent Type 2 Diabetes
by: Se Hee Min, et al.
Published: (2015-12-01)

UKPDS 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects.
by: Widjaja, A, et al.
Published: (1997)

MULTICENTER TRIAL OF MIGLITOL IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES
by: Stratton, I, et al.
Published: (1992)

Erratum: Effects of three months diet after diagnosis of type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45) (Diabetic Medicine (2000) 17 (518-523))
by: Manley, SE, et al.
Published: (2001)

Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45). UK Prospective Diabetes Study Group.
by: Manley, SE, et al.
Published: (2000)

Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment
by: Yeoree Yang, et al.
Published: (2016-10-01)

Effects of three months' diet after diagnosis of type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45) (vol 17, pg 518, 2000)
by: Manley, SE, et al.
Published: (2001)

Evaluation of the efficiency and safety of therapy with a combination of sulfonylurea derivatives and insulin sensitizers for type 2 diabetes mellitus
by: O N Goncharenko, et al.
Published: (2012-08-01)

Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy.
by: Rachman, J, et al.
Published: (1997)

Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45)
by: Manley, SE, et al.
Published: (2000)

Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
by: Pearson, E, et al.
Published: (2006)

Early transition from insulin to sulfonylureas in neonatal diabetes and follow-up: experience from China
by: Li, Xiuzhen, et al.
Published: (2018)

Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes.
by: Cook, M, et al.
Published: (2005)

Sulfonylureas in the modern strategy of therapy of type 2 diabetes
by: Lyudmila Viktorovna Nedosugova
Published: (2011-06-01)

NON-SULFONYLUREA A4166 STIMULATES INSULIN IN TYPE-2 DIABETES AND REDUCES POSTPRANDIAL GLUCOSE EXCURSION BY 64-PERCENT
by: Levy, J, et al.
Published: (1995)

A case with relapsed transient neonatal diabetes mellitus treated with sulfonylurea, ending chronic insulin requirement
by: Akihiko Ando, et al.
Published: (2018-04-01)

Consensus recommendations on sulfonylurea & sulfonylurea combinations in the management of Type 2 diabetes mellitus - international task force
by: Sanjay Kalra, et al.
Published: (2019-01-01)

Within-Sulfonylurea-Class Evaluation of Time to Intensification with Insulin (ZODIAC-43).
by: Dennis Schrijnders, et al.
Published: (2016-01-01)

Sulfonylurea: Personalized Medicine for Type 2 Diabetes
by: You-Cheol Hwang
Published: (2015-12-01)

The sulfonylurea receptor.
by: Ashcroft, S, et al.
Published: (1992)

Commentary on “Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus: International Task Force”
by: S K Singh
Published: (2018-01-01)